Department of Veterans Affairs, Office of Research and Development (VA)

Agency/Department

FLC Region

Security Lab

No

Address

810 Vermont Ave (NW)
Washington, DC 20420
United States

Want more information? Contact a representative below.

Laboratory Representative

Description

 

VA’s Research and Development program (VA Research), with its distinguished history of discovery and innovation dating back to 1925, today remains an essential part of VA’s efforts to ensure the health and wellbeing of our nation’s Veterans. The fundamental mission of VA Research is to advance the health and care of Veterans. It is part of the Veterans Health Administration, America’s largest integrated health care systems with over 1,700 sites of care, serving 8.3 million Veterans each year. With a state of-the-art electronic health record, VA Research is uniquely positioned to conduct pioneering research.

 

With the unique combination of accessible data, a national research setting with linked infrastructure, and a large research population, VA Research is renowned for conducting large-scale clinical trials and comparative effectiveness research. With more than 70 percent of VA researchers also providing care to patients, the program is poised to quickly move innovations and discoveries from the research setting to the care setting. Findings from clinical research, considered with findings from genomics and health services research, VA Research provides evidence-based information that can be used to enhance VA’s ability to provide personalized health care, care tailored to a specific patient’s circumstances. By giving VA providers such evidence-based information about an intervention’s effectiveness, the research helps guide providers as they consider various health care options and inform patients to participate in care decisions.

Mission

The Office of Research and Development (ORD) aspires to discover knowledge, develop VA researchers and health care leaders, and create innovations that advance health care for our Veterans and the Nation. ORD is headquartered in Washington, DC and has an estimated 3,000 investigators and 10,000 research staff located at 119 VA Medical Centers (VAMCs around the country. VA Research is an intramural research program that also embraces its close ties with academic affiliates, other federal agencies, nonprofit organizations, and private industry. By partnering with others who have common research interests, VA Research is able to leverage resources and expand the impact of federal research investments.

ORD consists of four research services that together form a cohesive whole to explore all phases of veterans' healthcare needs. Each Service oversees a number of world renowned research centers nationwide.

The Biomedical Laboratory Research & Development Service conducts research that explores basic biological or physiological principles in humans or animals but does not involve intact human beings. For example, it includes research on animal models and investigations of tissues, blood or other biologic specimens from humans

The Clinical Science Research and Development Service conducts research that focuses on intact human beings as the unit of examination. Examples include interventional and effectiveness studies, clinical, epidemiological and technological studies.

The Health Services Research and Development Service pursues research at the interface of health care systems, patients and health care outcomes. HSR&D underscores all aspects of VA health care; specifically quality, access, patient outcomes and health care costs.

The Rehabilitation Research & Development Service is dedicated to the well-being of America's veterans through a full spectrum of research: from approved rehabilitation research projects, through evaluation and technology transfer to final clinical application.

Each of these four services is headed by a director who is supervised by the Chief Research and Development Officer (CRADO), who in turn reports to the Deputy Under Secretary for Health for Policy and Services.

Technology Disciplines

Technologies
Displaying 1 - 10 of 287
 
A System and Method for Positioning and Supporting an Exercise Machine for use in a Hospital Bed (M-PACE)
A High Current, Radio Frequency Coupled Microstimulator for Autonomic Applications
A Surgically Implantable Urinary Incontinence Device
Acridone compounds
Acridone compounds
Activating extraction of demineralized bone matrix
Activation of quiescent stem cells
Acyl CoA:cholesterol acyltransferase (ACAT-2)
Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
Alpha B-crystallin as a therapy for ischemia or inflammation

Pages

Facilities

No Facilities

Equipment

No Equipment

Programs

No Programs

Funds

No Funds

Publications

No Publications

Successes

No Successes

Licenses
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 26, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to Fillauer Companies, Inc., 210 Amnicola Highway, Chattanooga, TN 37406, an exclusive license to U.S. Patent Nos. 9,549,827; 10,105,243; 10,376,388; and U.S. Patent Application Serial No. 16/404,777, associated with VA Invention Disclosure number 10-083 titled, “Improvements to Passive Ankle-Foot Prosthesis Capable of Automatic Adaptation to Sloped Walking Surfaces”.

Dates:
Comments must be received on or before September 10, 2021.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 19, 2021

The present invention provides methods of treating an auditory impairment associated with outer hair cells of the cochlea in a subject. The method may comprise administering to said subject an effective amount of a composition comprising, as an active agent, an oligonucleotide sequence having a portion of a mammalian telomere sequence so as to reduce the auditory impairment thereby treating the auditory impairment in the subject.

Dates:
Comments must be received by September 3, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to Weinberg Medical Physics, Ltd. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 19, 2021

A mask can comprise a covering material that is sufficiently sized to extend over a mouth and a
nose on a head of a wearer. The covering material can have an outer surface and an inner
surface. The covering material can define an opening therethrough. At least one transparent
membrane can be coupled to the covering material and cover the opening in the covering
material. The at least one transparent membrane can define a hole therethrough. An elongate
conduit can define an interior passage having a central axis. The elongate conduit can be
coupled to the at least one transparent membrane so that the central axis of the interior passage is
aligned with the hole. The mask can further comprise at least one securing element for securing
the mask to the head of the wearer.

Dates:
Comments must be received by September 3, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to Dravon Medical, Inc. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 16, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to Apex Foot Health Industries, 400 Frank W. Burr Blvd. Suite #240, Teaneck, NJ 07666, an exclusive license to VA’s rights in US Patent Nos. 10,292,452 and 10,779,612 and all foreign counterparts, associated with VA Invention Disclosure number 2015-060 titled, “Rocker Shoe Development Kit”.

Dates:
Comments must be received on or before August 31, 2021
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 16, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to ResQ Pharma, Inc., 2242 W. Harrison St., Ste. 201, Chicago, Illinois 60612, an exclusive license to VA’s rights in International Patent Application Nos. PCT/US2018/012623 and PCT/US2019/033997 and U.S. Patent Application Nos. 16/476,404 and 17/058,545 and all foreign counterparts, associated with VA Invention Disclosure numbers 2020-096 and 2020-147 titled, “Methods for Decreasing Injuries Associated with Intraoperative Hypotension” and “Lipid Emulsions and Uses Thereof”.

Dates:
Comments must be received on or before August 31, 2021.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateJul 22, 2021

VA intends to offer Avanzarx Pharmaceutical Holdings, LLC an exclusive license to technology called "Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors" by Goldblum et al., VA ID 2019-175

Dates:
July 22, 2021 through August 6, 2021
Address:
U.S. Department of Veterans Affairs Technology Transfer Program (14RDTT) 810 Vermont Ave, NW Washington, DC 20420
For further information contact:

David Marks
U.S. Department of Veterans Affairs
Technology Transfer Program (14RDTT)
810 Vermont Ave, NW
Washington, DC 20420
Office: 202-443-5609
email: david.marks2@va.gov

Supplementary information:
Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent to exclusively license
Publication DateApr 02, 2021

The Department of Veterans Affairs, Office of Research and Development, Technology Transfer Program, intends to grant to RevolutioNICE, Inc., 259 Stephens Street, Belleville, New Jersey, an exclusive license.

Dates:
April 2 through April 16, 2021
Address:
810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

David Marks (202) 443-5609

Supplementary information:

License will cover U.S. Patent Application 63/034,123 filed on June 3, 2020, U.S. Patent Application 63/153,661 filed on February 25, 2021, and any related patent applications associated with VA Invention Disclosure number 2020-334 titled, “Mobile Isolation Enclosure”. The mobile isolation device protects healthcare workers from being infected with viruses, bacteria, and other microorganisms while treating a patient.

Correction:
Updated Notice of Intent to License
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateMar 25, 2021

As stated in the original notice of January 25, 2021, the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Griffon Pharmaceuticals, an exclusive license to U.S. Patent Application No. 16/611,147 and PCT/US2018/031261, associated with VA Invention Disclosure number 2016-145 titled, “Methods and Composition for Treating Liver Disease”. However, Griffon Pharmaceuticals’ corporate entity and address for this license agreement have changed to the following: Griffon Pharmaceuticals International SA, Route de la Corniche 3, Bâtiment SE-A, 1066 Épalinges, Switzerland.

Dates:
Notice issued March 25, 2021; Comments must be received on or before April 14, 2021.
Address:
Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov
For further information contact:

Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as Griffon Pharmaceuticals. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateFeb 26, 2021

The present invention relates to the use of Cyclo-Z to stimulate cell growth and immune system components, and to modulate levels of several components involved in inflammation and autoimmune diseases, which may be helpful in fighting infectious agents as well as be useful in treating allergies, inflammation, and autoimmune diseases.

Dates:
Comments must be received by March 15, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to NovMetaPharma Co., Ltd. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent to Exclusive License
Publication DateFeb 17, 2021

Mobile isolation device that protects health-care workers from aerosolized pathogens while treating a patient. The device surrounds the head of the bed and the patient's head and chest. It can easily be moved from one bed to another. It height is adjustable.

Dates:
February 17, 2021
Address:
Department of Veterans Affairs Technology Transfer Program (14RDTT) 810 Vermont Ave, NW Washington, DC 20420 Office: 202-443-5609
For further information contact:

David Marks

Supplementary information:
Correction:
Send Inquiry

Pages